A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

Inclusion Criteria:

- Type 1 diabetes

- HbA1c (glycosylated haemoglobin) below or equal to 8.5%

- Current treatment with IGlar (insulin glargine) in a basal-bolus regimen with a total
daily dose below 120 U

- BMI (body mass index) below 35 kg/m^2

Exclusion Criteria:

- Use within the last 3 months prior to visit 1 (screening) of any antidiabetic glucose
lowering drug other than insulin/insulin analogues

- Subjects with regular use of acetaminophen who are not willing to use another
analgetic during CGM (Continuous Glucose Monitoring) periods

- Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronary
arterial bypass graft or angioplasty within 24 weeks prior to visit 1

- Recurrent severe hypoglycemia (more than one severe hypoglycemic event during the
last 12 months) or hypoglycemia unawareness or hospitalization for diabetic
ketoacidosis during the previous 6 months